Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.

Tettero, J.m., Freeman, S., Buecklein, V., Venditti, A., Maurillo, L., Kern, W., et al. (2022). Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. HEMASPHERE, 6(1), e676 [10.1097/HS9.0000000000000676].

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Venditti, Adriano;Buccisano, Francesco
2022-01-01

Abstract

Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.
2022
Online ahead of print
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Con Impact Factor ISI
http://dx.doi.org/10.1097/HS9.0000000000000676
Tettero, J.m., Freeman, S., Buecklein, V., Venditti, A., Maurillo, L., Kern, W., et al. (2022). Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party. HEMASPHERE, 6(1), e676 [10.1097/HS9.0000000000000676].
Tettero, Jm; Freeman, S; Buecklein, V; Venditti, A; Maurillo, L; Kern, W; Walter, Rb; Wood, Bl; Roumier, C; Philippé, J; Denys, B; Jorgensen, Jl; Bene, Mc; Lacombe, F; Plesa, A; Guzman, Ml; Wierzbowska, A; Czyz, A; Ngai, Ll; Schwarzer, A; Bachas, C; Cloos, J; Subklewe, M; Fuering-Buske, M; Buccisano, F
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Technical_Aspects_of_Flow_Cytometry_based.5.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 2.83 MB
Formato Adobe PDF
2.83 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/283491
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 18
social impact